Advertisement
News
Subscribe to Drug Discovery & Development News

The Lead

Biogen Slides as MS Drug Linked to Inflammation

October 22, 2014 | Comments

Shares of Biogen Idec slumped 8% after the pharmaceutical said a patient who took its newest multiple sclerosis drug suffered a brain inflammation and later died. Read more...                            

TOPICS:
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

PhosImmune, PureMHC Working Together on Cancer Immunotherapies

October 22, 2014 1:28 pm | Comments

PhosImmune Inc. and PureMHC LLC announced they have entered into a license and collaboration agreement to develop novel antibody-based immunotherapies designed to target cancers. Read more...

TOPICS:

Taiho Receives FDA Fast Track for Cancer Treatment

October 22, 2014 1:14 pm | Comments

Taiho Oncology Inc. announced that the FDA granted Fast Track designation for TAS-102 (nonproprietary names: trifluridine and tipiracil hydrochloride), an oral combination anticancer drug under investigation for the treatment of refractory metastatic colorectal cancer (mCRC). Read more...

TOPICS:

Study Finds Drugs Still in Recalled Supplements

October 22, 2014 11:48 am | by Lindsey Tanner, AP Medical Writer | Comments

Dietary supplements containing potentially dangerous prescription drug ingredients may still be for sale even years after safety recalls, a study found. Read more...                              

TOPICS:
Advertisement

Actavis Signs Option to Acquire Rhythm Subsidiary

October 22, 2014 10:24 am | Comments

Actavis plc, a leading global specialty pharmaceutical company, and Rhythm, a biopharmaceutical company, announced that Actavis has been granted an exclusive option to acquire Rhythm's wholly owned subsidiary, Rhythm Health Inc. Read more...

TOPICS:

12,000 Boxes of Pain Relief Tablets Are Being Recalled

October 22, 2014 10:20 am | Comments

12,000 boxes of pain relief tablets sold at are being recalled because the cartons contain a different medication that could cause allergic reactions. Read more...                 

TOPICS:

Improved Data Reveals Higher Global Burden of Tuberculosis

October 22, 2014 10:13 am | Comments

Recent intensive efforts to improve collection and reporting of data on tuberculosis (TB) are shedding new light on the epidemic, revealing that there are almost half a million more cases of the disease than previously estimated. Read more...

TOPICS:

Johnson & Johnson Announces New Spending Plan for Ebola Vaccine

October 22, 2014 10:05 am | Comments

Johnson & Johnson announced that it has made a commitment of up to $200 million to accelerate and significantly expand the production of an Ebola vaccine program in development at its Janssen Pharmaceutical Companies. Read more...                    

TOPICS:

Oramed Gets Positive Data From Oral Insulin Trial

October 22, 2014 10:03 am | Comments

Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, reported positive top-line clinical results from its Phase 2a clinical trial of ORMD-0801, the company's proprietary oral insulin capsules, to treat type 1 diabetes. Read more...

TOPICS:
Advertisement

Rho Awarded New Federal Contract

October 21, 2014 2:46 pm | Comments

Rho, a contract research organization (CRO) providing clinical research services in both the commercial and federal market, has been awarded the renewal of their existing federal contract with the National Institute of Dental and Craniofacial Research (NIDCR). Read more...

TOPICS:

Neurocrine Announces Phase 3 Study for Inhibitor

October 21, 2014 2:40 pm | Comments

Neurocrine Biosciences Inc. announced that it has initiated a Phase 3 clinical trial (Kinect 3 Study) of its proprietary Vesicular Monoamine Transporter 2 compound, NBI-98854.  Read more...                    

TOPICS:

Researchers Demonstrate Advances in Creating Blood Cancer Treatment

October 21, 2014 2:33 pm | Comments

Researchers at NYU Langone Medical Center and elsewhere said that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. Read more...    

TOPICS:

Lilly's Diabetes Treatment Receives NDA

October 21, 2014 2:19 pm | Comments

FDA has accepted the filing of a NDA for empagliflozin plus immediate-release metformin hydrochloride fixed-dose combination, an investigational compound being studied for the treatment of adults with type 2 diabetes (T2D). Read more...       

TOPICS:

Once CD8 T Cells Take on One Virus, They'll Fight Others Too

October 21, 2014 2:02 pm | Comments

Scientists think of CD8 T cells as long-lived cells that become tuned to fight just one pathogen, but a study finds that once CD8 T cells fight one pathogen, they also join the body's "innate" immune system, ready to answer the calls of the cytokine signals that are set off by a wide variety of infections. Read more...

TOPICS:

Supercomputers Link Proteins to Drug Side Effects

October 21, 2014 1:46 pm | Comments

Lawrence Livermore National Laboratory researchers have discovered a high-tech method of using supercomputers to identify proteins that cause medications to have certain adverse drug reactions (ADR) or side effects. Read more...         

TOPICS:

RegeneRx Proceeds With Phase 3 Eye Drop Study

October 21, 2014 10:43 am | Comments

RegeneRx announced that it met with the FDA in September and as a result of the meeting may begin Phase 3 to evaluate RGN-259 preservative-free eye drops for the treatment of patients with neurotrophic keratopathy (NK), an orphan disease of the cornea. Read more...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading